Home » News » 12/05 » Lundbeck launches new anti-depressant study

Lundbeck launches new anti-depressant study

Date published: 12/12/2005

Lundbeck has started the phase I clinical studies with Lu AA24530. The study will look into the tolerability and the pharmacokinetic profile of the drug, which was selected after preclinical animal models suggested fast onset of action and increased efficacy in the treatment of depression.

Peter Hongaard Andersen, head of research at Lundbeck, said: "It is with pleasure that Lundbeck brings this new drug candidate into clinical development. "Lu AA24530 is the first of a number of candidates with novel actions expected to enter clinical development within the coming years."

The research will centre on developing drug candidates that are treating unmet needs experienced by patients on existing treatments. Through detailed understanding of the underlying biology in depression Lundbeck's research has identified novel mechanisms that may improve future treatment.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.